Sun 27 July 2008
 

Welcome to MedNous

MedNous is an independent journal and website that covers advances in medicine in Europe.

It carries exclusive information and interviews about the drugs and diagnostics that will dominate tomorrow’s healthcare industry.

MedNous is of special interest to scientists, investors, patent lawyers, regulators and pharmaceutical executives who are shaping the future of medicine.

Are patent backlogs creating an unequal playing field?
  • For a discussion of this issue, please see the interview with Alison Brimelow, president, European Patent Office, in the July-August 2008 issue of MedNous.
  • Subscribers can download the PDF version available from your Control Panel

Headlines

Roche to acquire developer of a new antibody platform

Roche said that it has agreed to pay C$191 million in cash for a Canadian biotechnology company, ARIUS Research Inc, which has developed a new antibody platform.


-- 24 July 2008

READ MORE [item no. 381]

Use of norfloxacin-containing medicines to be restricted

The European Medicines Agency has recommended restrictions on the oral use of medicines containing norfloxacin for the treatment of urinary infections.


-- 24 July 2008

READ MORE [item no. 380]

Further headlines and news


Download current issue of MedNous
The current issue is now available as a downloadable PDF from
your
subscribers Control Panel

Featured article

Read in full (free to view)

Power to the FDA

There is at least one forum every year where biopharmaceutical executives can pose questions directly to the management of the US Food and Drug Administration’s Center for Drug Evaluation and Research. This is the ‘CDER Town Meeting’ at the annual meeting of the Drug Information Association (DIA).

This year the hot topic was drug safety. Nearly everyone at the June 2008 meeting in Boston, Massachusetts was eager to find out how the FDA planned to use new powers on drug safety which were granted to it under the Food and Drug Administration Amendments Act of 2007. Signed into law in September 2007, the FDAAA gives the agency the authority to require companies to conduct post-marketing studies, prepare risk-management plans for drugs that pose unusual safety problems and to swiftly implement boxed warnings with new safety information. Previously the agency could ask companies to undertake corrective measures if safety problems arose, but it could not fall back on statutory powers to enforce these instructions.

Conference delegates were eager to find out how the FDAAA had changed the work practices and priorities at the agency.

John Jenkins, director of the Office of New Drugs, said the legislation was being implemented gradually. It is a complex law with many provisions. But there was no question that it empowered the FDA to act swiftly and decisively whenever it identified new problems. He cited product labelling as an example.

In the past, if the FDA spotted a safety problem, it could ask companies to add a boxed warning to their product labels. It would then monitor compliance. In cases where a group of drugs required a boxed warning, it would discuss the label changes with the manufacturers on a case-by-case basis. Under the new legislation, the agency will be able to require companies to make these changes immediately.


-- 21 July 2008

READ MORE [item no.2]